Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00329472
Recruitment Status : Withdrawn (poor enrollment)
First Posted : May 24, 2006
Last Update Posted : August 27, 2010
Information provided by:
Samsung Medical Center

Brief Summary:
This study is randomized phase III trial designed to assess whether (preoperative) neoadjuvant chemotherapy followed by surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (experimental treatment) improves 3-year disease-free survival, compared to surgery plus adjuvant chemotherapy with gemcitabine and cisplatin (standard treatment) in stage IB, IIA, IIB and T3N1 non-small cell lung cancer

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: gemcitabine, cisplatin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Plus Adjuvant Chemotherapy Versus Surgery Plus Adjuvant Chemotherapy in Stage IB, IIA, IIB and T3N1 Non-small Cell Lung Cancer (ICON)
Study Start Date : April 2006
Estimated Primary Completion Date : July 2010
Estimated Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Gem/Cis
neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
Drug: gemcitabine, cisplatin
No Intervention: no neoadjuvant chemotherapy

Primary Outcome Measures :
  1. 3-year disease-free survival

Secondary Outcome Measures :
  1. overall survival
  2. pattern of relapse
  3. quality of life
  4. operative mortality and toxicity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven NSCLC patients
  • All patients must have:Clinical stage IB, IIA, IIB and T3N1 by mediastinoscopy, Chest CT and PET-CT
  • 18 year of ages or older
  • ECOG performance status 0-1
  • Uni-dimensionally measurable lesion by RECIST criteria
  • No prior chemotherapy or radiotherapy for NSCLC
  • Pre-operative FEV1 ≥ 2.0 L evaluated within 28 days
  • Adequate bone marrow function: Hb > 9.0 g/dL, WBC ≥ 4,000/μL, platelet count ≥ 100,000/μL
  • Adequate liver and renal function: Total bilirubin < 2 x ULN, AST/ALT < 3 x ULN, serum creatinine ≤ 1.5 mg/dL, creatinine clearance ≥ 60 mL/min
  • Written informed consent

Exclusion Criteria:

  • Superior sulcus tumor
  • Prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer at least 5 years
  • Uncontrolled systemic illness such as DM, CHF, unstable angina or arrhythmia
  • Recent myocardial infarction within 6 months
  • Patients with post-obstructive pneumonia or serious infection
  • Pregnant or nursing women (Women of reproductive potential have to agree to use an effective contraceptive method.)
  • Patients with psychological problem

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00329472

Sponsors and Collaborators
Samsung Medical Center
Principal Investigator: Keunchil Park, M.D. Samsung Medical Center

Responsible Party: Keunchil Park/Professor, Samsung Medical Center Identifier: NCT00329472     History of Changes
Other Study ID Numbers: 2004-09-027
First Posted: May 24, 2006    Key Record Dates
Last Update Posted: August 27, 2010
Last Verified: July 2010

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs